Madrigal Pharma Buys Gene Therapy Assets from Arrowhead

Ticker: MDGL · Form: 8-K · Filed: Mar 15, 2024 · CIK: 1157601

Sentiment: bullish

Topics: acquisition, gene-therapy, pipeline-expansion

Related Tickers: ARWR

TL;DR

Madrigal buys gene therapy pipeline from Arrowhead for $150M upfront + milestones. Big move into rare disease gene therapy.

AI Summary

Madrigal Pharmaceuticals, Inc. announced on March 14, 2024, that it has entered into a definitive agreement to acquire a portfolio of gene therapy programs from Arrowhead Pharmaceuticals, Inc. for an upfront payment of $150 million, plus potential milestone payments and royalties. This acquisition is expected to significantly expand Madrigal's pipeline in rare diseases.

Why It Matters

This strategic acquisition diversifies Madrigal's therapeutic focus and adds promising gene therapy candidates to its pipeline, potentially leading to new treatments for rare diseases.

Risk Assessment

Risk Level: medium — The acquisition involves significant upfront and potential future payments, and the success of gene therapy programs carries inherent development and regulatory risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily to announce Madrigal Pharmaceuticals, Inc.'s entry into a definitive agreement to acquire a portfolio of gene therapy programs from Arrowhead Pharmaceuticals, Inc.

What is the upfront payment for the acquisition?

The upfront payment for the acquisition of the gene therapy programs is $150 million.

Who is the seller of the gene therapy programs?

The seller of the gene therapy programs is Arrowhead Pharmaceuticals, Inc.

What is the date of the definitive agreement?

The date of the definitive agreement is March 14, 2024.

What type of therapeutic programs is Madrigal acquiring?

Madrigal is acquiring a portfolio of gene therapy programs.

Filing Stats: 689 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-03-14 18:47:35

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. MADRIGAL PHARMACEUTICALS, INC. By: /s/ Mardi Dier Name: Mardi Dier Title: Senior Vice President and Chief Financial Officer Date: March 14, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing